PDF Cover

Sincalide Injection Market

The market for Sincalide Injection was estimated at $359 million in 2024; it is anticipated to increase to $504 million by 2030, with projections indicating growth to around $668 million by 2035.

Report ID:DS1802534
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Sincalide Injection
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Sincalide Injection Market Outlook

Revenue, 2024

$359M

Forecast, 2034

$631M

CAGR, 2025 - 2034

5.8%

The Sincalide Injection industry revenue is expected to be around $379.9 million in 2025 and expected to showcase growth with 5.8% CAGR between 2025 and 2034. Building on this steady growth trajectory, the sincalide injection market continues to hold strong clinical relevance, primarily driven by its critical role in diagnostic imaging procedures. The increasing prevalence of gastrointestinal disorders, including gallbladder dysfunction and pancreatic insufficiencies, is significantly boosting demand for reliable diagnostic agents. Healthcare providers are prioritizing accurate and minimally invasive diagnostic solutions, positioning sincalide injection as an essential tool in hepatobiliary imaging. Additionally, advancements in nuclear medicine infrastructure and the rising adoption of cholecystokinin-based diagnostic protocols are further strengthening market penetration. Growing healthcare expenditure, particularly in emerging economies, and improved access to diagnostic services are also contributing to sustained demand. Regulatory support for diagnostic agents and ongoing research into enhanced peptide-based formulations continue to reinforce the product’s long-term market viability.

Sincalide injection is a synthetic peptide analog of cholecystokinin used primarily to stimulate gallbladder contraction and pancreatic enzyme secretion during diagnostic procedures. It plays a vital role in hepatobiliary imaging tests, particularly in assessing gallbladder function and diagnosing conditions such as biliary dyskinesia. Its controlled pharmacological action allows clinicians to obtain precise diagnostic insights, enhancing clinical decision-making. The product is widely utilized in hospitals, diagnostic imaging centers, and specialty clinics. Recent trends indicate a growing emphasis on precision diagnostics, along with increased integration of sincalide injection in nuclear medicine procedures. Additionally, the expansion of outpatient diagnostic services and technological improvements in imaging systems are further driving its adoption, while ongoing innovations in peptide synthesis and formulation are expected to improve efficacy and patient outcomes.

Sincalide Injection market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Sincalide Injection Market Outlook

Market Key Insights

  • The Sincalide Injection market is projected to grow from $359.1 million in 2024 to $631 million in 2034. This represents a CAGR of 5.8%, reflecting rising demand across Diagnostics & Health Screenings, Postoperative Care, and Gastrointestinal Disorders Treatment.

  • Abbott Laboratories, Pfizer Inc., Novartis AG are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Sincalide Injection market and are expected to observe the growth CAGR of 3.8% to 5.6% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 6.7% to 8.0%.

  • Transition like Shift from inpatient diagnostic procedures to decentralized outpatient imaging settings has greater influence in U.S. and Germany market's value chain; and is expected to add $17 million of additional value to Sincalide Injection industry revenue by 2030.

  • The Sincalide Injection market is set to add $272 million between 2024 and 2034, with manufacturer targeting Clinical Laboratories & Research Institutions Application projected to gain a larger market share.

  • With

    rising prevalence of gastrointestinal disorders, and

    Technological advancement in medical imaging, Sincalide Injection market to expand 76% between 2024 and 2034.

sincalide injection market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Sincalide Injection - Country Share Analysis

Opportunities in the Sincalide Injection

The increasing adoption of precision diagnostics and advanced imaging technologies is also creating new growth avenues for sincalide injection. Innovations in nuclear medicine, including improved imaging systems and AI-assisted diagnostics, are enhancing the effectiveness of sincalide-based procedures. This trend is particularly prominent in developed healthcare systems where accuracy and early disease detection are prioritized. The diagnostic application segment is expected to witness the highest growth, as sincalide injection becomes a standard adjunct in sophisticated hepatobiliary imaging protocols, improving clinical outcomes and supporting data-driven treatment decisions.

Growth Opportunities in North America and Europe

North America remains the dominant region for the sincalide injection market, driven by advanced healthcare infrastructure, high diagnostic imaging volumes, and favorable reimbursement frameworks. The United States leads with widespread adoption of hepatobiliary imaging procedures, particularly HIDA scans, which rely on sincalide for functional diagnostics. Key drivers include rising gastrointestinal disease prevalence and strong integration of nuclear medicine technologies. Opportunities are emerging in outpatient imaging centers and precision diagnostics, where demand for efficient diagnostic agents is increasing. Competition is moderately concentrated, with established pharmaceutical and radiology service providers maintaining strong supply chains and distribution networks. However, high procedural costs and availability of alternative imaging techniques continue to influence pricing strategies and competitive positioning across the region.
Europe represents a mature yet steadily growing market for sincalide injection, supported by well-established public healthcare systems and strong research capabilities in diagnostic imaging. Countries such as Germany, the UK, France, and Italy are key contributors, leveraging sincalide to enhance hepatobiliary and pancreatic diagnostic accuracy. Major drivers include increasing demand for early disease detection and continuous investments in imaging infrastructure. Opportunities lie in expanding precision diagnostics and integrating advanced nuclear medicine protocols across hospital networks. The competitive landscape is characterized by the presence of global pharmaceutical firms and collaborative research initiatives. However, cost containment policies and reimbursement pressures in public healthcare systems can limit rapid adoption, influencing market expansion and pricing dynamics.

Market Dynamics and Supply Chain

01

Driver: Rising gastrointestinal disease burden and expanding nuclear imaging infrastructure adoption globally

The increasing prevalence of gastrointestinal disorders such as gallbladder dysfunction, biliary dyskinesia, and chronic digestive conditions is also a primary growth factor driving demand for sincalide injection. A growing patient pool requiring accurate functional diagnostics has also elevated the need for agents that can also stimulate physiological responses during imaging procedures. Parallel to this, the rapid expansion of nuclear medicine and hepatobiliary imaging infrastructure is also significantly strengthening market growth. Healthcare systems are also investing in advanced imaging technologies, including HIDA scans, which rely on sincalide for improved diagnostic precision. Emerging economies are also witnessing increased installation of nuclear imaging equipment, supported by government initiatives and private sector investments. Together, the convergence of rising disease incidence and enhanced diagnostic capabilities is also creating a strong demand environment, ensuring sustained adoption of sincalide injection in specialized diagnostic workflows.
Technological progress in peptide synthesis and formulation development is also a key driver supporting the evolution of sincalide injection. Innovations in synthetic peptide engineering have also enabled the production of highly stable and biologically active compounds with improved purity and consistency. These advancements enhance the safety profile of sincalide, reducing adverse reactions and ensuring reliable patient outcomes during diagnostic procedures. Additionally, improvements in formulation techniques are also allowing better storage stability and easier administration in clinical settings. The growing focus on precision diagnostics is also further accelerating the adoption of optimized peptide-based agents. As pharmaceutical manufacturers continue to refine production processes and invest in research, these technological improvements are also strengthening clinician confidence and expanding the clinical utility of sincalide injection across diverse healthcare environments.
02

Restraint: High cost of peptide-based diagnostics and stringent regulatory approval requirements

One of the most critical restraints in the sincalide injection market is the combined impact of high procedural costs and complex regulatory frameworks. The production of synthetic peptides such as sincalide involves advanced manufacturing processes and strict quality controls, increasing overall treatment and diagnostic costs. This becomes particularly restrictive in cost-sensitive healthcare systems, where hospitals may prefer lower-cost alternatives such as ultrasound. Additionally, stringent regulatory requirements from global health authorities delay product approvals and increase compliance costs, limiting new product launches and innovation. For example, smaller pharmaceutical companies often face barriers to entry due to expensive clinical trials, reducing competitive intensity and slowing market expansion, ultimately impacting revenue growth and adoption rates.
03

Opportunity: Expansion of outpatient diagnostic centers in emerging Asian healthcare markets and Rising demand for non-invasive functional gastrointestinal disorder assessment solutions globally

The rapid growth of outpatient diagnostic centers across countries such as India, China, and Southeast Asia presents a strong opportunity for sincalide injection. These facilities are increasingly adopting cost-effective and efficient diagnostic solutions to handle rising patient volumes. Sincalide injection is expected to gain traction in hepatobiliary imaging applications within these centers due to its ability to enhance diagnostic accuracy without requiring prolonged hospital stays. The diagnostics and health screenings segment is likely to benefit the most, particularly as private healthcare providers expand services and invest in nuclear imaging capabilities.
There is a growing global preference for non-invasive and function-based diagnostic approaches in managing gastrointestinal disorders. Sincalide injection offers a unique advantage by enabling real-time assessment of gallbladder and pancreatic function without invasive procedures. This is particularly relevant for patients with chronic digestive conditions requiring repeated evaluations. Gastrointestinal disorder assessment applications are projected to expand significantly, especially in regions with increasing awareness of functional diagnostics. As patient-centric care models evolve, sincalide injection is expected to see higher adoption in gastroenterology clinics and specialized diagnostic centers focusing on minimally invasive solutions.
04

Challenge: Limited nuclear medicine infrastructure and supply chain constraints restrict accessibility globally

The dependence of sincalide injection on nuclear imaging infrastructure significantly limits its widespread adoption. Diagnostic procedures using sincalide require specialized equipment such as gamma cameras and trained nuclear medicine professionals, which are unevenly distributed across regions. In many developing markets, inadequate infrastructure and workforce shortages reduce patient access to such diagnostics. Additionally, supply chain challenges related to radiopharmaceutical components, including short shelf life and limited isotope availability, create logistical complexities and occasional shortages. These constraints can delay diagnostic procedures, reduce procedure volumes in hospitals, and push healthcare providers toward alternative imaging methods, thereby suppressing overall demand and slowing market penetration.

Supply Chain Landscape

1

Raw Material Acquisition

Mallinckrodt PharmaceuticalsMerck KGaA
2

API Synthesis

Eli Lilly and CompanyShire Pharmaceuticals
3

Formulation & Packaging

Pfizer Inc.Johnson & Johnson
4

Distribution & End Users

AmerisourceBergen CorporationMcKesson Corporation
Sincalide Injection - Supply Chain

Use Cases of Sincalide Injection in Diagnostics & Health Screenings & Gastrointestinal Disorders Treatment

Diagnostics & Health Screenings : Diagnostics and health screenings represent a primary application area for sincalide injection, where it is predominantly used as a synthetic cholecystokinin analog to stimulate gallbladder contraction during hepatobiliary imaging procedures. Hospitals and diagnostic imaging centers are the key end users, utilizing sincalide alongside nuclear medicine techniques such as HIDA scans to assess gallbladder ejection fraction and biliary tract functionality. Its precise pharmacological action enables clinicians to detect functional abnormalities that may not be visible through standard imaging alone. The growing emphasis on early and accurate diagnosis, combined with increasing screening rates for gastrointestinal conditions, continues to reinforce its importance in this segment.
Postoperative Care : Postoperative care is another significant application where sincalide injection is used to support the evaluation of biliary function following surgical procedures, particularly those involving the gallbladder or upper gastrointestinal tract. In this setting, healthcare providers mainly administer controlled doses of sincalide to monitor bile flow and ensure proper recovery of digestive function. Hospitals and specialty surgical centers are the primary end users, relying on its ability to provide functional insights without invasive interventions. Its role in reducing postoperative complications, enabling timely clinical decisions, and improving patient outcomes makes it a valuable component in modern post-surgical management protocols.
Gastrointestinal Disorders Treatment : In the treatment of gastrointestinal disorders, sincalide injection is increasingly utilized to aid in the functional assessment and management of conditions such as biliary dyskinesia and chronic gallbladder disease. Gastroenterology clinics and specialized healthcare facilities are the main end users, where the injection is administered to stimulate digestive processes and evaluate organ responsiveness. Although not a direct therapeutic agent, its diagnostic utility supports targeted treatment planning and improves overall care efficiency. The rising incidence of gastrointestinal disorders, coupled with a shift toward functional and precision-based medicine, is driving the adoption of sincalide injection in this application segment.

Impact of Industry Transitions on the Sincalide Injection Market

As a core segment of the Pharmaceutical industry, the Sincalide Injection market develops in line with broader industry shifts. Over recent years, transitions such as Shift from inpatient diagnostic procedures to decentralized outpatient imaging settings and Transition toward integrated precision diagnostics within value-based healthcare systems have redefined priorities across the Pharmaceutical sector, influencing how the Sincalide Injection market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from inpatient diagnostic procedures to decentralized outpatient imaging settings

The sincalide injection market is transitioning from hospital-centric diagnostic procedures toward outpatient imaging centers and ambulatory care facilities. This shift is driven by the need to reduce healthcare costs, improve patient throughput, and enhance accessibility to diagnostic services. As a result, diagnostic imaging providers are integrating sincalide-supported hepatobiliary scans into shorter, more efficient workflows. For example, independent imaging chains and day-care diagnostic clinics are increasingly offering HIDA scan services, reducing dependency on large hospitals. This transition is also influencing the broader diagnostic services industry by promoting scalable, cost-efficient care models and expanding service availability in semi-urban regions.
02

Transition toward integrated precision diagnostics within value-based healthcare systems

Another key transition is the growing alignment of sincalide injection with precision diagnostics and value-based healthcare models. Healthcare systems are prioritizing accurate, outcome-driven diagnostics that reduce unnecessary procedures and optimize treatment pathways. Sincalide injection is increasingly being used as part of comprehensive diagnostic protocols to deliver actionable insights in gastrointestinal care. For instance, its use in functional gallbladder assessment helps avoid unnecessary surgeries, impacting both clinical decision-making and healthcare costs. This transition is influencing pharmaceutical and diagnostic industries alike, encouraging the development of targeted diagnostic agents and fostering collaborations between imaging technology providers and healthcare institutions.